July 28, 2020 / 10:55 AM / 13 days ago

CORRECTED-Pfizer profit falls 32% as global trial of COVID-19 vaccine candidate begins

(Corrects year-earlier net income figure to 89 cents from 91 in paragraph 2; the story was previously corrected to show that net income in the latest quarter was 61 cents, not 62.)

July 28 (Reuters) - Pfizer Inc reported a 32% fall in second-quarter profit on Tuesday due to a dip in demand for some of its drugs from the COVID-19 pandemic and from rising competition, as the company and partner began a global study into a vaccine candidate to fight the health crisis.

The U.S. drugmaker said net income fell to $3.43 billion, or 61 cents per share, in the quarter, from $5.05 billion, or 89 cents per share, a year earlier.

Sales fell to $11.80 billion from $13.26 billion.

Pfizer and German biotech BioNTech drugmaker said on Monday they would begin a pivotal global study to evaluate their lead COVID-19 vaccine candidate. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below